Simulations Plus, Inc. · NASDAQ:SLP
Simulations Plus — Technical Presentation (March 2024)
40 slides from Simulations Plus's technical presentation, Mar 20, 2024
Slide 1: Unlocking the Power of PBPK Modeling: PBPK for First-in-Human and Beyond
Unlocking the Power of PBPK Modeling: PBPK for First-in-Human and Beyond March 20, 2024 1 NASDAQ: SLP
Slide 2: Outline
Outline Proof PBPK Works for FIH PK Predictions Regulatory Perspective Breaking Down the Components of a PBPK Model Uncertainty and Sensitivity Model Applications 2 NASDAQ: SLP
Slide 3: Considerations
Considerations Use everything that you know, but keep the model as simple as possible Aim to use PBPK not empirical modelling Combine compound specific data with physiology as they are intimately interconnected and explicable only by reference to the whole Preclinical verification can increase t
Slide 4: Considerations
Considerations Always include uncertainty Never give single point estimates Be realistic with your expectations A successful prediction gets the category right or within 2-fold, but not necessarily matching values exactly Sensitivity analysis and model application can inform future decisions A
Slide 5: Proof PBPK Works for FIH PK Predictions
Proof PBPK Works for FIH PK Predictions “In the majority of cases, PBPK gave more accurate predictions of pharmacokinetic parameters and plasma concentration-time profiles than the Dedrick approach.” “This evaluation demonstrates that PBPK models can lead to reasonable predictions of human pharmacok
Slide 6: Proof PBPK Works for FIH PK Predictions
Proof PBPK Works for FIH PK Predictions “The simulation results using PBPK were shown to be superior to those obtained via traditional one compartment analyses. In many cases, this difference was statistically significant.” “Our prospective human PK prediction methods yielded good prediction results
Slide 7: Regulatory Guidance for PBPK Modelling
Regulatory Guidance for PBPK Modelling “Primarily for drug developers, FIH “PBPK modelling is a state-of-the-art modelling tool for assessing an prediction using PBPK is important for appropriate starting dose for healthy volunteers.[…] The methods used decision-making and allows additional and calc
Slide 8: An Industry Defined FIH PBPK Strategy
An Industry Defined FIH PBPK Strategy Flow diagrams for each essential component of a FIH prediction using PBPK modelling 8 NASDAQ: SLP
Slide 9: Use Everything You Know
Use Everything You Know FIH Simulator includes the major preclinical species to enable you to move seamlessly from mouse, rat, dog, minipig, rabbit, cyno through to human in one platform – The overall risk profile can be assessed in ADMET Predictor – Inputs without measured data can be predicted usi
Slide 10: Use Everything You Know: Start with QSPR + PBPK
Use Everything You Know: Start with QSPR + PBPK BDDCS – Biopharmaceutics Drug Disposition Classification System ECCS – Extended Clearance Classification System QSPR – Quantitative Structure-Property Relationship BCS – Biopharmaceutic Classification System 10 NASDAQ: SLP
Slide 11: Use Everything You Know: Compound Assessment Using QSPR + PBPK
Use Everything You Know: Compound Assessment Using QSPR + PBPK 11 NASDAQ: SLP
Slide 12: Use Everything You Know: Critical Thinking Using QSPR + PBPK
Use Everything You Know: Critical Thinking Using QSPR + PBPK Cutoff between low and high permeability is 1.2cm/s x 10^4 based on metoprolol ECCS, S+ Mechanistic Clearance Classification and transporter substrate predictions are in the notes 12 NASDAQ: SLP
Slide 13: Use Everything You Know: Pragmatic Assessment Using QSPR + PBPK
Use Everything You Know: Pragmatic Assessment Using QSPR + PBPK Blue – Plasma concentration Red – Amount dissolved Cyan – Amount absorbed Multiple options to predict clearance: models for HLM, hepatocytes, enzyme kinetics 13 NASDAQ: SLP
Slide 14: Preclinical Verification to Better Predict Human PK
Preclinical Verification to Better Predict Human PK Distribution BPR blood/plasma ratio Fup fraction unbound in plasma, Kp tissue-to-plasma partition coefficient, QWBA Quantitative Whole Body Autoradiography, 14 SpecPStc specific in-vivo diffusional clearance per millilitre of tissue cell volume. NA
Slide 15: Preclinical Verification: Assessing the Pieces of the Jigsaw Puzzle
Preclinical Verification: Assessing the Pieces of the Jigsaw Puzzle FIH prediction for IV dosing of Tobramycin : Distribution Data • Preclinical IV Cp vs Time profiles • Use the Lukacova Kp equation • LogP/D • Input available measured data • pKa • PBPK record per preclinical species • Fraction unbou
Slide 16: Preclinical Verification: Applying Critical Thinking
Preclinical Verification: Applying Critical Thinking FIH prediction for IV dosing of Tobramycin : Distribution Assess Model • Predicted Vss is too large causing a rapid • No measured RBP, set as 1-haematocrit distribution to tissues and a slow return to • Use a permeability limited tissue model to s
Slide 17: Preclinical Verification: Applying Critical Thinking
Preclinical Verification: Applying Critical Thinking FIH prediction for IV dosing of Tobramycin : Distribution Species Observed Vss Predicted Vss Pred/Obs Rat 0.093 L 0.190 L 2.0 Dog 12.24 L 16.63 L 1.4 17 NASDAQ: SLP
Slide 18: Verification Defines Strategy for Human Prediction
Preclinical Verification Defines Strategy for Human Prediction Distribution -Tobramycin 18 NASDAQ: SLP
Slide 19: Preclinical Verification to Better Predict Human PK
Preclinical Verification to Better Predict Human PK Metabolism and Elimination CLR renal clearance CLR,u unbound renal clearance ECCS Extended Clearance Classification System Fup fraction unbound in plasma GFR glomerular filtration rate 19 NASDAQ: SLP IVIVE in-vitro in-vivo extrapolation.
Slide 20: Verification: Combining Measured Data with Predicted Properties
Preclinical Verification: Combining Measured Data with Predicted Properties Metabolism and Elimination Data • Renal clearance from IV studies • Observed or in vitro biliary clearance data • Validate CLR prediction • Microsomal, hepatocyte or • Adjust CLR settings in the kidney enzyme kinetic data ti
Slide 21: Verification: Combining Measured Data with Predicted Properties
Preclinical Verification: Combining Measured Data with Predicted Properties Metabolism and Elimination Data • Renal clearance from IV studies • Microsomal, hepatocyte or enzyme kinetic data • Observed biliary clearance data 21 NASDAQ: SLP
Slide 22: Preclinical Verification to Better Predict Human PK
Preclinical Verification to Better Predict Human PK Oral Absorption ASF absorption scale factors BSSR bile salt solubilisation ratio MPT mean precipitation time Efflux transporters can be incorporated in GastroPlus models with a simple method (e.g. adjusting permeability based on preclinical observa
Slide 23: Verification: Building on the IV Model
Preclinical Verification: Building on the IV Model FIH prediction for PO dosing of Cilostazol : Oral Absorption Data • Moderately lipophilic • Set IV model – compartmental distribution • Essentially neutral at physiological pH and NCA CL to enable the oral absorption to • Low to moderate solubility
Slide 24: Verification: Assessing the sensitive parameters
Preclinical Verification : Assessing the sensitive parameters FIH prediction for PO dosing of Cilostazol : Oral Absorption 24 NASDAQ: SLP
Slide 25: Verification: Additional measured data to enable prediction
Preclinical Verification : Additional measured data to enable prediction FIH prediction for PO dosing of Cilostazol : Oral Absorption Assess Model • Dissolution is the rate limiting step for • Fit distribution to particle size data absorption • Apply to model • Solubility has been fitted to measured
Slide 26: Verification: Additional measured data to enable prediction
Preclinical Verification : Additional measured data to enable prediction FIH prediction for PO dosing of Cilostazol : Oral Absorption • Fit distribution to particle size data • Apply to model • Verify with other doses / species / formulations Blue – Plasma concentration Red – Amount dissolved 26 NAS
Slide 27: Verification Defines Strategy for Human Prediction
Preclinical Verification Defines Strategy for Human Prediction Oral Absorption - Cilostazol 27 NASDAQ: SLP
Slide 28: Preclinical Verification to Better Predict Human PK
Preclinical Verification to Better Predict Human PK Gut Wall Metabolism CLint hepatic intrinsic clearance Fg fraction of drug escaping gut wall metabolism Km concentration of substrate at half Vmax Vmax maximum velocity or rate of enzyme catalyzed reaction 28 NASDAQ: SLP Gut wall metabolism is often
Slide 29: Verification: Gap Analysis
Preclinical Verification: Gap Analysis FIH prediction for PO dosing of Cilostazol : Gut Wall Metabolism Data • CYP3A4 is predicted to metabolise • Metabolism data Cilostazol, which is also present in the • Prediction of the human CL gut • Incorporate learnings from preclinical PO • Isoforms involved
Slide 30: Verification: Extrapolation to Human
Preclinical Verification: Extrapolation to Human FIH prediction for PO dosing of Cilostazol : Gut Wall Metabolism Assess Model • Predicted human CLh is approximately 40% of liver blood flow • Simulated profile using the predicted enzyme kinetics results in a Fh of ~59% • Fg in human is predicted to
Slide 31: Verification Defines Strategy for Human Prediction
Preclinical Verification Defines Strategy for Human Prediction Gut Wall Metabolism 31 NASDAQ: SLP
Slide 32: Always Include Uncertainty
Always Include Uncertainty 32 NASDAQ: SLP
Slide 33: Understanding the Sensitive Parameters: Planning for the Future
Understanding the Sensitive Parameters: Planning for the Future • Will micronisation improve the oral exposure? • If CL or Vss is uncertain, is an IV microdose study recommended? • Will dosing with food improve the duration of action or decrease the oral exposure? • Will further modelling be require
Slide 34: Model Application Beyond FIH: Additional Learning
Model Application Beyond FIH: Additional Learning • Modelling high dose PK data in preclinical species to enable the prediction of Toxicology dose levels and frequency – To aid in the design of these pivotal supporting studies • Predicting the PK in the target population in addition to healthy volun
Slide 35: Model Application Beyond FIH: Inform Your Clinical Plan
Model Application Beyond FIH: Inform Your Clinical Plan • Models developed using the FIH Simulator can be used to: – predict the possibility of DDIs with your test compound as the victim or the perpetrator – Consider additional dosage routes • This does require the purchase of additional modules 35
Slide 36: Regulatory Applications
Regulatory Applications 31 Organizations (innovator & generic companies combined) Fig. 1 Regulatory Applications of GastroPlus® (PBBM/PBPK Modeling) in the Pharmaceutical Industry (Years 2020-2022): Results from Survey 36 NASDAQ: SLP
Slide 37: Considerations
Considerations • Use everything that you know, but keep the model as simple as possible – Aim to use PBPK not empirical modelling – Combine compound specific data with physiology as they are intimately interconnected and explicable only by reference to the whole • Preclinical verification can increa
Slide 38: References
References Slide 10 1Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20. 2Wu CY, Benet LZ. Predicting drug disposition via applicatio
Slide 39: References
References Slide 19 1Mathialagan S, Piotrowski MA, Tess DA, Feng B, Litchfield J, Varma MV. Quantitative prediction of human renal clearance and drug-drug interactions of organic anion transporter substrates using in vitro transport data: a relative activity factor approach. Drug Metab Dispos. 2017;
Slide 40: Interested in learning more? Contact
Interested in learning more? Contact: Becky Graves Director, Simulation Studies [email protected] Peter Kilford, Ph.D. Associate Vice President, Software Business Development [email protected] simulations-plus.com/fih simulations-plus.learnupon.com/store 40 NASDAQ: S
Simulations Plus — Technical Presentation (March 2024) on 6ix